A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Trial end date:
2019-03-07
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as
reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle
function in patients with ALS.